R-Pharm became the first Russian company to obtain FDA’s permission to conduct clinical trials in the USA

R-Pharm owns the rights for development and commercialization of olokizumab. The product phase III clinical trials will run in Russia, the European Union, Asia and the USA. Olokizumab is a monoclonal antibody against interleukin 6, a mediator of inflammatory and autoimmune processes in human organism. The new drug will be tested…

Read more

High Cost Nosologies (VZN) program spending grew by 0.8% in rubles in 2014

The dollar value decreased by 10.1% at the same time. Segment volume in packs increased by 13.1%. The total value was 39.92 billion rubles (1.16 billion USD) with an average price per pack of 12 945.6 rubles (11% less than in 2013). Generics launch and/or declining drug prices primarily caused segment value stagnation. Program…

Read more

The Russian pharmaceutical market is expected to grow by 12-18% and reach 1.268 trillion rubles in 2015, according to IMS Health forecast

The increase in drug prices will drive the growth, which will take place mainly in the unregulated segment. This change should be more pronounced in the first half of the year. Ruble depreciation and inflation will be the main causes of rising drug prices. Analysts predict that Russia may become the eighth largest pharmaceutical market in the world by 2017.

Read more

The Ministry of Health of the Russian Federation will raise prices of drugs in the Essential Drug List priced below 50 rubles by 30%

The Minister Veronika Skvortsova commented, «These 30% will allow manufacturers to maintain profitability, prevent stock-out and retain cheaper drugs on the market." Essential Drug List drug prices increased by 5.7% in the first quarter of 2015 while remaining within the maximum allowed limits. This means that prices of regulated drugs are stable. Prices of the rest of the drugs on the market went up by 16.9% during the same period.

Read more

The Motley Fool investment company published the rating of most profitable healthcare companies

Americans alone spend $3 billion on healthcare every year, which makes the market very attractive to companies. Most profitable companies with market capitalization greater than $200 million are rated in the table below.

Read more

Russian drug reimbursement market grew 4% and totaled 86.869 billion rubles in 2014 according to Russia DLO

At the same time both market volume and market dollar value decreased by 4% and 11%, respectively. Market volume amounted to 85.036 million packs. Market dollar value reached 2.366 billion USD. Top-rated products are shown in the table below by their generic names. Average price per pack in reimbursement was 27.82 USD versus 30.09 USD in the previous year.

Read more

Hospital market grew 15% in volume and amounted to 729.785 packs in 2014 according to Russia Hospital Audit

The growth was observed both in rubles (+25%) and dollars (+2%). The market totaled 159.421 billion rubles (4.045 billion USD) in wholesale prices. The rating of TOP-10 trade names is shown in the table below. Average price per pack declined 0.73 USD versus 2013 and amounted to 5.58 USD.

Read more

Retail market volume dropped by 0.4% and amounted to 4.215 billion packs in 2014 according to Russia Retail Audit

At the same time market value grew 12% in rubles and totaled 491.826 billion. Market dollar value amounted to 12.803 billion, which is 8% less than in 2013 due to a significant depreciation of the ruble. Market value numbers are calculated in wholesale prices. Average price per pack of finished pharmaceutical products was 3.90…

Read more